As of early 2026, China has surpassed the West in the number of active CAR-T clinical trials. For a medical tourist, this means access to more treatment targets (CD19, CD22, BCMA, and Claudin 18.2) and significantly shorter waiting lists. The best CAR-T cell therapy hospitals in China for international patients include Shanghai Ruijin Hospital, Peking Union Medical College Hospital (PUMCH), and the GoBroad Healthcare Group — all offering JCI-accredited care at 20–30% of US costs.
Key Facts
- China has more active CAR-T clinical trials than any other country as of early 2026.
- Ruijin Hospital (Shanghai) reports an approximately 80% three-month complete remission rate for relapsed lymphoma in international patients.
- Treatment costs at leading Chinese CAR-T hospitals run at 20–30% of equivalent US costs.
- Boao Lecheng (Hainan) offers zero-tariff access to therapies approved abroad but not yet widely available across mainland China.
- CAR-T treatment cycle duration for international patients: 4–6 weeks including infusion and mandatory inpatient monitoring.
Table of Contents
Why Choose China for CAR-T Therapy in 2026?
The Best CAR-T Cell Therapy Hospitals in China for international patients in 2026 include Shanghai Ruijin Hospital, Peking Union Medical College Hospital (PUMCH), and the GoBroad Healthcare Group. These facilities offer JCI-accredited care, bilingual support, and access to advanced cell therapies like Fucaso and Yorwida at 20–30% of US costs.
China has surpassed the West in the number of active CAR-T clinical trials as of early 2026, offering more treatment targets and shorter waiting lists. For a complete overview of cancer treatment modalities available in China, see our Cancer Treatment in China guide.
Top hospitals feature International Medical Centers designed for foreign patient logistics. According to the WHO global cancer burden data, blood cancers — including lymphoma, leukemia, and multiple myeloma — collectively affect millions of patients worldwide each year, driving urgent demand for accessible advanced therapies.
For a full cost breakdown, see our CAR-T Cell Therapy Cost in China vs USA: 2026 Comparison Guide.
Top 3 Best CAR-T Cell Therapy Hospitals in China
1. Ruijin Hospital (Shanghai) – Best for Commercial Excellence
Affiliated with Shanghai Jiao Tong University, Ruijin is the gold standard for hematology in China. By early 2026, Ruijin had treated hundreds of international patients with a three-month complete remission rate of approximately 80% for relapsed lymphoma — a result comparable to the ~83% ORR achieved in the pivotal ZUMA-1 trial of axicabtagene ciloleucel for large B-cell lymphoma. Ruijin’s outcomes in Multiple Myeloma patients similarly parallel the efficacy seen in the landmark CARTITUDE-1 trial of ciltacabtagene autoleucel.
Key advantages:
- International Medical Center (Building 10) with hotel-style suites
- Direct billing with global insurers
- English-speaking clinical coordinators throughout the 4–6 week treatment cycle
2. GoBroad Healthcare Group (Beijing & Shanghai) – Best for Patient Logistics
GoBroad specializes in end-to-end service for foreign patients. They are pioneers in sequential CAR-T and offer streamlined S2 Medical Visa support and dedicated English-speaking coordinators at every step.
Key advantages:
- Proven track record with international patients
- Seamless visa documentation support
- Access to both Beijing and Shanghai facilities
3. Peking Union Medical College Hospital (Beijing) – Best for Complex Cases
PUMCH is consistently ranked as China’s #1 hospital. It leads in dual-target CAR-T constructs and research into solid tumor treatments, making it ideal for complex or refractory cases. For myeloma patients specifically, NCCN guidelines recommend anti-BCMA CAR-T constructs — the same class developed and administered at PUMCH — as a preferred option for relapsed/refractory disease. MD Anderson Cancer Center similarly identifies refractory blood cancers as the primary indication where CAR-T therapy has demonstrated transformative results.
Key advantages:
- Ranked #1 hospital in China
- Specialists in dual-target CAR-T (CD19 + CD22, BCMA + CD38)
- Strong internal medicine support for managing potential complications
Special Mention: Boao Lecheng (Hainan Island)
The Boao Lecheng International Medical Tourism Pilot Zone is a special economic zone offering zero-tariff access to innovative therapies approved abroad but not yet widely available in mainland China — including therapies like FDA-approved Abecma (idecabtagene vicleucel), which showed a 73% ORR in the KarMMa trial. For patients seeking CAR-T + PD-1 combination protocols or experimental therapies, Boao Lecheng provides a unique regulatory pathway. Mayo Clinic’s clinical overview of CAR-T notes that combination immunotherapy approaches remain an active area of investigation — precisely the category of trials accelerated through the Boao Lecheng zone.
READ MORE: Proton Therapy Cost in China vs. USA: 2026 Comparison Guide
Choosing the Right Facility: A 2026 ChecklistChoosing the Right Facility: A 2026 Checklist
When selecting a hospital, verify the following:
- S2 Visa Support: Does the hospital issue official medical invitation letters for the S2 Visa?
- Cell Lab Standards: Is the manufacturing lab GMP-certified?
- Language Support: Is 24/7 bilingual (English) translation available?
- Post-Infusion Monitoring: Does the hospital have on-site ICU capability for managing CRS?
For a step-by-step breakdown of what happens from arrival to discharge, see our CAR-T Treatment Timeline in China: 2026 Step-by-Step Guide.
